The clinical trial data (STEP 4 and the post-treatment follow-up from the Lundgren liraglutide trial) shows that most patients regain a substantial portion of their lost weight within 12 to 18 months of stopping a GLP-1, even after reaching goal
Metabolic and behavioral features of acute hyperpurinergia and the maternal immune activation mouse model of autism spectrum disorder
GLP-1 medications change in coverage effective January 1, 2026 [Press release]
No tiene usos teraputicos validados
Looney proposed that senescent tissues are increased in SLE target tissues and contribute to organ dysfunction, decreased activity and poor long term outcomes
Other states, including Florida, Georgia, and Tennessee, generally exclude GLP-1 weight loss shots from Medicaid coverage